Literature DB >> 16723595

Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis.

Carolina Serena1, Félix Gilgado, Marçal Mariné, F Javier Pastor, Josep Guarro.   

Abstract

We have evaluated the efficacy of voriconazole (VRC) in a systemic infection by Trichosporon asahii in immunosuppressed guinea pigs. VRC was more effective than amphotericin B in prolonging survival and reducing tissue burden. The best results were obtained with VRC at 10 mg/kg of body weight/day.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16723595      PMCID： PMC1479129          DOI： 10.1128/AAC.00045-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Uncommon opportunistic fungi: new nosocomial threats.

Authors:  A H Groll; T J Walsh
Journal:  Clin Microbiol Infect       Date:  2001       Impact factor: 8.067

2.  Multidrug-resistant Trichosporon asahii isolates are susceptible to voriconazole.

Authors:  Rama Falk; Dana G Wolf; Mervyn Shapiro; Itzhack Polacheck
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

3.  Trichosporon asahii, a non-Candida yeast that caused fatal septic shock in a patient without cancer or neutropenia.

Authors:  J R Ebright; M R Fairfax; J A Vazquez
Journal:  Clin Infect Dis       Date:  2001-07-26       Impact factor: 9.079

4.  Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.

Authors:  P H Chandrasekar; J Cutright; E Manavathu
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

Review 5.  Trichosporon beigelii infection: experience in a regional burn center.

Authors:  M J Cawley; G R Braxton; L R Haith; K J Reilly; R E Guilday; M L Patton
Journal:  Burns       Date:  2000-08       Impact factor: 2.744

6.  Trichosporon species infection in bone marrow transplanted patients.

Authors:  M L Moretti-Branchini; K Fukushima; A Z Schreiber; K Nishimura; P M Papaiordanou; P Trabasso; R Tanaka; M Miyaji
Journal:  Diagn Microbiol Infect Dis       Date:  2001-03       Impact factor: 2.803

7.  Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.

Authors:  O Uzun; S Arikan; S Kocagöz; B Sancak; S Unal
Journal:  Diagn Microbiol Infect Dis       Date:  2000-10       Impact factor: 2.803

8.  In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

Authors:  S J Roffey; S Cole; P Comby; D Gibson; S G Jezequel; A N R Nedderman; D A Smith; D K Walker; N Wood
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

Review 10.  Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.

Authors:  S Fournier; W Pavageau; M Feuillhade; S Deplus; A-M Zagdanski; O Verola; H Dombret; J M Molina
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-11-01       Impact factor: 3.267
View more
  9 in total

1.  The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.

Authors:  Marçal Mariné; Vinicius Leite Pedro Bom; Patricia Alves de Castro; Lizziane Kretli Winkelstroter; Leandra Naira Ramalho; Neil Andrew Brown; Gustavo Henrique Goldman
Journal:  Virulence       Date:  2015-03-09       Impact factor: 5.882

2.  In vitro interaction of itraconazole with amphotericin B, caspofungin, and terbinafine against clinical isolates of Trichosporon asahii.

Authors:  Houmin Li; Jianjun Qiao; Zhe Wan; Jianzhong Zhang
Journal:  Mycopathologia       Date:  2010-12-14       Impact factor: 2.574

Review 3.  Current knowledge of Trichosporon spp. and Trichosporonosis.

Authors:  Arnaldo L Colombo; Ana Carolina B Padovan; Guilherme M Chaves
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

Review 4.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

Authors:  H Ruth Ashbee; Rosemary A Barnes; Elizabeth M Johnson; Malcolm D Richardson; Rebecca Gorton; William W Hope
Journal:  J Antimicrob Chemother       Date:  2013-12-29       Impact factor: 5.790

5.  A novel silkworm infection model with fluorescence imaging using transgenic Trichosporon asahii expressing eGFP.

Authors:  Yasuhiko Matsumoto; Hideki Yamazaki; Yusuke Yamasaki; Yuki Tateyama; Tsuyoshi Yamada; Takashi Sugita
Journal:  Sci Rep       Date:  2020-07-03       Impact factor: 4.379

Review 6.  On and Under the Skin: Emerging Basidiomycetous Yeast Infections Caused by Trichosporon Species.

Authors:  Marçal Mariné; Neil Andrew Brown; Diego Mauricio Riaño-Pachón; Gustavo Henrique Goldman
Journal:  PLoS Pathog       Date:  2015-07-30       Impact factor: 6.823

7.  Antifungal susceptibility profile of Trichosporon isolates: correlation between CLSI and etest methodologies.

Authors:  Raquel M L Lemes; Juliana P Lyon; Leonardo M Moreira; Maria Aparecida de Resende
Journal:  Braz J Microbiol       Date:  2010-06-01       Impact factor: 2.476

8.  Epidemiology and Outcome of Trichosporon Fungemia: A Review of 185 Reported Cases From 1975 to 2014.

Authors:  Yong Liao; Xuelian Lu; Suteng Yang; Yi Luo; Qi Chen; Rongya Yang
Journal:  Open Forum Infect Dis       Date:  2015-09-25       Impact factor: 3.835

Review 9.  Animal models: an important tool in mycology.

Authors:  Javier Capilla; Karl V Clemons; David A Stevens
Journal:  Med Mycol       Date:  2007-12       Impact factor: 4.076
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.